معرفی
Naing Lin Shan is a Postdoctoral Associate at the Yale School of Medicine, affiliated with the Department of Medical Oncology and Hematology. She holds a PhD in Microbiology and Molecular Genetics from Rutgers University, an MS in Clinical and Translational Science, and an MBBS from the University of Medicine, Mandalay.
- PhD, Rutgers University, Microbiology and Molecular Genetics
- MS, Rutgers University, Clinical and Translational Science
- MBBS, University of Medicine, Mandalay
Her research focuses on breast cancer biology, particularly cancer stem cells, metabolic isozyme targets, and intratumoral heterogeneity. She investigates how vitamin D compounds and targeted therapies affect tumor progression, and applies artificial intelligence to clinical decision-making. Current projects include genomic alterations in pre-cancerous tissues and antibody-drug conjugate development.
Recent publications highlight her work on ctDNA as a biomarker for residual disease after chemotherapy, metabolic reprogramming in cancer, and AI-based diagnostic tools. She has earned awards such as the Basic Science Scholar Award (2024) and Anthony Lu Best Paper Award (2021).
- Basic Science Scholar Award, 2024
- Anthony Lu Best Paper Award, 2021
- Biomedical Completion and Acceleration Fellowship, 2020
- Excellence Fellowship, 2014
Shan collaborates with researchers like Lajos Pusztai, Kim Blenman, and Michal Marczyk. Her work spans pre-clinical models, clinical trial analysis, and translational research at Yale, targeting pathways such as mTORC2, PEPCK2, and cancer stemness regulation.
